FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

rraoimigton,	D.O. 200 10	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average but	urden								
hours nor reenence:	0.5								

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Koppel Adam				2. Issuer Name and Ticker or Trading Symbol Solid Biosciences Inc. [SLDB]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner								
ı							3. Date of Earliest Transaction (Month/Day/Year) 12/13/2022							71		(give title	21	Other (below)	
200 CLARENDON STREET					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)							
(Street) BOSTON	N M	A (02116											X		iled by Mor		orting Person One Repo	
(City)	(St	ate)	(Zip)																
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)				Date	Execution Date,		Code (Instr. 5)			str. 3, 4 a	4 and Securities Beneficia Owned For		ities Forricially (D) of Following ted action(s)		m: Direct or Indirect Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
						Code V Amount (A) or (D) Price		,	Transact (Instr. 3										
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
		ransaction of ode (Instr. Derivative		Expiration Date Ar (Month/Day/Year) Se Ur De		7. Title and Amount of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)						
				Co	ode '	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amoun or Numbe of Shares						
Director Stock Option (Right to Buy)	\$6.47	12/13/2022			A		9,650		(1)	13	2/13/2032	Common Stock	9,650		\$0.00	9,650		D	

Explanation of Responses:

Remarks:

/s/ Adam Koppel

12/15/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{1.} This option was granted on December 13, 2022 and vests in full on the one-year anniversary of the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.